Cardiff Oncology, Inc. (CRDF) fundamentals score
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Its goal is to target tumor vulnerabilities with treatment combinations of onvansertib, its oral and highly selective PLK1 inhibitor, and standard-of-care ("SoC") therapeutics.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 4.3 out of 10, Weak long-term fundamentals
- Growth: 2.8/10
- Profitability: 3.3/10
- Financial health: 5.2/10
- Earnings quality: 7.0/10
- Valuation: 4.3/10
Scores are calculated from Cardiff Oncology, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10